Medscape Conference Coverage, based on selected sessions at the:
ECTRIMS 2007: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
October 11 - 14, 2007, Prague, Czech Republic
This activity is not sanctioned by, nor a part of, the European Committee for Treatment and Research in Multiple Sclerosis.
Topic OverviewsExpert InterviewsConference News- REGARD: Glatiramer Acetate, Interferon-Beta Equally Effective for MSA head-to-head study of interferon-beta and glatiramer acetate in multiple sclerosis found no significant difference in relapse rates; however, the study was underpowered because relapse rates were lower than expected.
Medscape Medical News, October 26, 2007 - Adding Daclizumab to Interferon-Beta May Reduce Brain Lesions in RRMSPreliminary phase 2 results show the addition of daclizumab, a monoclonal antibody, to interferon-beta helps reduce new or enlarged gadolinium-enhancing lesions in patients with relapsing-remitting MS.
Medscape Medical News, October 25, 2007 - Most Cases of "Benign" MS Progress After 20 Years, but Survival Is LongerA long-term study has found that the majority of patients diagnosed with "benign" multiple sclerosis progress after 20 years; however, they continue to survive significantly longer than do patients diagnosed with more serious forms of the disease.
Medscape Medical News, October 22, 2007 - CME Fluoxetine Shows Promise in Multiple SclerosisThe antidepressant fluoxetine may help reduce the number of new gadolinium-enhancing lesions in multiple sclerosis, data from a small, single-center clinical trial indicate.
Medscape Medical News, October 16, 2007 - CME Simvastatin Does Not Antagonize Interferon-Beta, Interim Analysis SuggestsInterim analysis of the ongoing SIMCOMBIN trial suggests that statins do not diminish the effects of interferon-beta in patients with multiple sclerosis.
Medscape Medical News, October 15, 2007 - CME DNA Vaccine Alters Natural Course of Multiple SclerosisA newly developed DNA vaccine appeared to fundamentally alter the disease course of multiple sclerosis in patients with relapsing remitting multiple sclerosis.
Medscape Medical News, October 8, 2007
|
Legal Disclaimer
The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the European Committee for Treatment and Research in Multiple Sclerosis. These materials and the related activity are not sanctioned by the European Committee for Treatment and Research in Multiple Sclerosis or the commercial supporter of the conference and do not constitute an official part of that conference.
Copyright © 2007 Medscape.
